1. Identifying Patients With Early, Progressive RA: Where Do We Stand Today?

2. Intro: Biomarkers in RA

3. The Importance of Biomarkers: 2010 ACR/EULAR RA Classification Criteria

4. ACPA vs RF: Specificity/Sensitivity

5. Case Discussion: Patient With Early RA

6. Patient Evaluation

7. Citrullination

8. Anti-PAD4 Associations: Disease Duration and Anti-CCP

9. Genetic and Environmental Contributions to RA Pathogenesis

12. Treatment Plan

13. ACPA Signals Worsened Prognosis

14. Additional Poor Prognostic Indicators in RA

15. PAD4 and Radiographic Damage

16. Treat Presymptomatic ACPA-Positive Patients?

17. Test First-Degree Relatives?

18. Patient Follow-Up, 3 Months

19. Development of RA: Genetic Risk

20. RA, ACPAs, and Smoking

21. Impact of Baseline ACPA Level on Treatment Efficacy: AMPLE Trial

22. Can ACPA Status Affect Treatment Response?

23. Concluding Remarks

24. Abbreviations

25. Abbreviations (cont)